SEARCH

SEARCH BY CITATION

References

  • Bacigalupo, A., Lamparelli, T., Bruzzi, P., Guidi, S., Alessandrino, P.E., di Bartolomeo, P., Oneto, R., Bruno, B., Barbanti, M., Sacchi, N., Van Lint, M.T. & Bosi, A. (2001) Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood, 98, 29422947.
  • Bacigalupo, A., Lamparelli, T., Barisione, G., Bruzzi, P., Guidi, S., Alessandrino, P.E., di Bartolomeo, P., Oneto, R., Bruno, B., Sacchi, N., van Lint, M.T. & Bosi, A. (2006) Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation, 12, 560565.
  • Blau, I.W., Basara, N., Lentini, G., Guenzelmann, S., Kirsten, D., Schmetzer, B., Bischoff, M., Roemer, E., Kiehl, M.G. & Fauser, A.A. (2001) Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study. Bone Marrow Transplantation, 27, 2733.
  • Chakraverty, R., Peggs, K., Chopra, R., Milligan, D.W., Kottaridis, P.D., Verfuerth, S., Geary, J., Thuraisundaram, D., Branson, K., Chakrabarti, S., Mahendra, P., Craddock, C., Parker, A., Hunter, A., Hale, G., Waldmann, H., Williams, C.D., Yong, K., Linch, D.C., Goldstone, A.H. & Mackinnon, S. (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood, 99, 10711078.
  • Craddock, C., Szydlo, R.M., Dazzi, F., Olavarria, E., Cwynarski, K., Yong, A., Brookes, P., de la Fuente, J., Kanfer, E., Apperley, J.F. & Goldman, J.M. (2001) Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. British Journal of Haematology, 112, 228236.
  • Craddock, C., Nagra, S., Peniket, A., Brookes, C., Buckley, L., Nikolousis, E., Duncan, N., Tauro, S., Yin, J., Liakopoulou, E., Kottaridis, P., Snowden, J., Milligan, D., Cook, G., Tholouli, E., Littlewood, T., Peggs, K., Vyas, P., Clark, F., Cook, M., Mackinnon, S. & Russell, N. (2010) Factors predicting long term survival after T cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica, 95, 989995.
  • Eapen, M., Horowitz, M.M., Klein, J.P., Champlin, R.E., Loberiza, F.R., Jr, Ringden, O. & Wagner, J.E. (2004) Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. Journal of Clinical Oncology, 22, 48724880.
  • Eapen, M., Logan, B.R., Confer, D.L., Haagenson, M., Wagner, J.E., Weisdorf, D.J., Wingard, J.R., Rowley, S.D., Stroncek, D., Gee, A.P., Horowitz, M.M. & Anasetti, C. (2007) Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biology of Blood Marrow Transplantation, 13, 14611468.
  • Filipovich, A.H. (2008) Diagnosis and manifestations of chronic graft-versus-host disease. Best Practical Research in Clinical Haematology, 21, 251257.
  • Fine, J.P. & Gray, R.J. (1999) A proportional hazards model for the subdistribution of a competing risk. JASA, 94, 496509.
  • Finke, J., Bethge, W.A., Schmoor, C., Ottinger, H.D., Stelljes, M., Zander, A.R., Volin, L., Ruutu, T., Heim, D.A., Schwerdtfeger, R., Kolbe, K., Mayer, J., Maertens, J.A., Linkesch, W., Holler, E., Koza, V., Bornhauser, M., Einsele, H., Kolb, H.J., Bertz, H., Egger, M., Grishina, O. & Socie, G. (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology, 10, 855864.
  • Friedrichs, B., Tichelli, A., Bacigalupo, A., Russell, N.H., Ruutu, T., Shapira, M.Y., Beksac, M., Hasenclever, D., Socie, G. & Schmitz, N. (2010) Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncology, 11, 331338.
  • Gallardo, D., de la Camara, R., Nieto, J.B., Espigado, I., Iriondo, A., Jimenez-Velasco, A., Vallejo, C., Martin, C., Caballero, D., Brunet, S., Serrano, D., Solano, C., Ribera, J.M., de la Rubia, J. & Carreras, E. (2009) Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study Haematologica, 94, 12821288.
  • Garderet, L., Labopin, M., Gorin, N.C., Polge, E., Fouillard, L., Ehninger, G.E., Ringden, O., Finke, J., Tura, S. & Frassoni, F. (2003) Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. Bone Marrow Transplantation, 31, 2329.
  • Goldstone, A.H. & Rowe, J.M. (2009) Transplantation in adult ALL. Hematology American Society Hematology Educational Program, 2009, 593601.
  • Gray, R.J. (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics, 16, 11411154.
  • Hale, G., Zhang, M.J., Bunjes, D., Prentice, H.G., Spence, D., Horowitz, M.M., Barrett, A.J. & Waldmann, H. (1998) Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood, 92, 45814590.
  • Kennedy-Nasser, A.A., Bollard, C.M., Myers, G.D., Leung, K.S., Gottschalk, S., Zhang, Y., Liu, H., Heslop, H.E., Brenner, M.K. & Krance, R.A. (2008) Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biology of Blood and Marrow Transplantation, 14, 12451252.
  • Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S., Peggs, K., Verfuerth, S., Pettengell, R., Marsh, J.C., Schey, S., Mahendra, P., Morgan, G.J., Hale, G., Waldmann, H., de Elvira, M.C., Williams, C.D., Devereux, S., Linch, D.C., Goldstone, A.H. & Mackinnon, S. (2000) In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood, 96, 24192425.
  • Lee, D.H., Kwon, Y.J., Lim, J., Kim, Y., Han, K., Chung, N.G., Jeong, D.C., Cho, B. & Kim, H.K. (2009) Comparable outcomes of HLA-matched unrelated and HLA-identical sibling donor bone marrow transplantation for childhood acute myeloid leukemia in first remission. Pediatric Transplantation, 13, 210216.
  • Ljungman, P., Bregni, M., Brune, M., Cornelissen, J., Witte, T.D., Dini, G., Einsele, H., Gaspar, H.B., Gratwohl, A., Passweg, J., Peters, C., Rocha, V., Saccardi, R., Schouten, H., Sureda, A., Tichelli, A., Velardi, A. & Niederwieser, D. (2009) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplantation, 45, 219234.
  • Malladi, R.K., Peniket, A.J., Littlewood, T.J., Towlson, K.E., Pearce, R., Yin, J., Cavenagh, J.D., Craddock, C., Orchard, K.H., Olavarria, E., McQuaker, G., Collin, M. & Marks, D.I. (2009) Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. Bone Marrow Transplantation, 43, 709715.
  • Marks, D.I., Bird, J.M., Vettenranta, K., Hunt, L., Green, A., Cornish, J.M., Goulden, N., Pamphilon, D.H., Steward, C.G. & Oakhill, A. (2000) T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. Biology of Blood and Marrow Transplantation, 6, 646653.
  • Miller, J.P., Perry, E.H., Price, T.H., Bolan, C.D., Jr, Karanes, C., Boyd, T.M., Chitphakdithai, P. & King, R.J. (2008) Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biology of Blood and Marrow Transplantation, 14, 2936.
  • Mohty, M., Bay, J.O., Faucher, C., Choufi, B., Bilger, K., Tournilhac, O., Vey, N., Stoppa, A.M., Coso, D., Chabannon, C., Viens, P., Maraninchi, D. & Blaise, D. (2003) Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood, 102, 470476.
  • Nichols, W.G., Corey, L., Gooley, T., Davis, C. & Boeckh, M. (2002) High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. Journal of Infectious Disease, 185, 273282.
  • Pavletic, Z.S., Joshi, S.S., Pirruccello, S.J., Tarantolo, S.R., Kollath, J., Reed, E.C., Bierman, P.J., Vose, J.M., Warkentin, P.I., Gross, T.G., Nasrati, K., Armitage, J.O., Kessinger, A. & Bishop, M.R. (1998) Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplantation, 21, 3341.
  • Pulsipher, M.A., Chitphakdithai, P., Miller, J.P., Logan, B.R., King, R.J., Rizzo, J.D., Leitman, S.F., Anderlini, P., Haagenson, M.D., Kurian, S., Klein, J.P., Horowitz, M.M. & Confer, D.L. (2009) Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood, 113, 36043611.
  • Rebello, P., Cwynarski, K., Varughese, M., Eades, A., Apperley, J.F. & Hale, G. (2001) Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy, 3, 261267.
  • Remberger, M., Ringden, O., Blau, I.W., Ottinger, H., Kremens, B., Kiehl, M.G., Aschan, J., Beelen, D.W., Basara, N., Kumlien, G., Fauser, A.A. & Runde, V. (2001) No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood, 98, 17391745.
  • Remberger, M., Beelen, D.W., Fauser, A., Basara, N., Basu, O. & Ringden, O. (2005) Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood, 105, 548551.
  • Ringden, O., Labopin, M., Bacigalupo, A., Arcese, W., Schaefer, U.W., Willemze, R., Koc, H., Bunjes, D., Gluckman, E., Rocha, V., Schattenberg, A. & Frassoni, F. (2002) Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. Journal of Clinical Oncology, 20, 46554664.
  • Schmitz, N., Beksac, M., Bacigalupo, A., Ruutu, T., Nagler, A., Gluckman, E., Russell, N., Apperley, J., Szerm, J., Bradstock, K., Buzyn, A., Schlegelberger, B., Matcham, J. & Gratwohl, A. (2005) Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica, 90, 643648.
  • Schmitz, N., Eapen, M., Horowitz, M.M., Zhang, M.J., Klein, J.P., Rizzo, J.D., Loberiza, F.R., Gratwohl, A. & Champlin, R.E. (2006) Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood, 108, 42884290.
  • Stem Cell Trialists’ Collaborative Group (2005) Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. Journal of Clinical Oncology, 23, 50745087.
  • Storek, J., Gooley, T., Siadak, M., Bensinger, W.I., Maloney, D.G., Chauncey, T.R., Flowers, M., Sullivan, K.M., Witherspoon, R.P., Rowley, S.D., Hansen, J.A., Storb, R. & Appelbaum, F.R. (1997) Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood, 90, 47054709.
  • Wagner, J.E., Thompson, J.S., Carter, S.L. & Kernan, N.A. (2005) Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II–III trial. Lancet, 366, 733741.